NASDAQ:CLRB - Cellectar Biosciences Stock Price, Forecast & News

Cellectar Biosciences trades on the NASDAQ under the ticker symbol "CLRB."

Cellectar Biosciences's stock reverse split on Tuesday, July 17th 2018. The 1-10 reverse split was announced on Friday, July 13th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 13th 2018. An investor that had 100 shares of Cellectar Biosciences stock prior to the reverse split would have 10 shares after the split.

Cellectar Biosciences Inc (NASDAQ:CLRB) announced its earnings results on Tuesday, November, 12th. The biopharmaceutical company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.38) by $0.04. View Cellectar Biosciences' Earnings History.

Cellectar Biosciences is scheduled to release their next quarterly earnings announcement on Tuesday, February 25th 2020. View Earnings Estimates for Cellectar Biosciences.

3 brokerages have issued 1-year target prices for Cellectar Biosciences' shares. Their forecasts range from $3.00 to $10.00. On average, they expect Cellectar Biosciences' share price to reach $6.33 in the next year. This suggests a possible upside of 145.5% from the stock's current price. View Analyst Price Targets for Cellectar Biosciences.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cellectar Biosciences in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cellectar Biosciences.

News coverage about CLRB stock has been trending very negative on Wednesday, InfoTrie Sentiment reports. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Cellectar Biosciences earned a coverage optimism score of -3.1 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the company's share price in the near future. View News Stories for Cellectar Biosciences.

Cellectar Biosciences saw a increase in short interest during the month of January. As of January 31st, there was short interest totalling 311,900 shares, an increase of 88.9% from the January 15th total of 165,100 shares. Based on an average daily trading volume, of 123,600 shares, the days-to-cover ratio is presently 2.5 days. Currently, 3.4% of the shares of the company are sold short. View Cellectar Biosciences' Current Options Chain.

Some companies that are related to Cellectar Biosciences include REDHILL BIOPHAR/S (RDHL), Chimerix (CMRX), Xeris Pharmaceuticals (XERS), Savara (SVRA), Aquestive Therapeutics (AQST), Zynerba Pharmaceuticals (ZYNE), IMMUTEP LTD/S (IMMP), Northwest Biotherapeutics (NWBO), Axovant Gene Therapies (AXGT), Trillium Therapeutics (TRIL), VERONA PHARMA P/S (VRNA), Sunesis Pharmaceuticals (SNSS), TFF Pharmaceuticals (TFFP), Trevi Therapeutics (TRVI) and AVEO Pharmaceuticals (AVEO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Cellectar Biosciences investors own include Hudbay Minerals (HBM), Zynga (ZNGA), Quantum (QTM), Baytex Energy (BTE), Sherritt International (S), Bombardier (BDRBF), Encana (ECA), Bombardier, Inc. Class B (BBD.B), Bonavista Energy (BNP) and Hudbay Minerals (HBM).

Cellectar Biosciences' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (2.12%) and Game Plan Financial Advisors LLC (0.46%). Company insiders that own Cellectar Biosciences stock include James V Caruso, Jarrod Longcor and Stephen A Hill. View Institutional Ownership Trends for Cellectar Biosciences.

CLRB stock was bought by a variety of institutional investors in the last quarter, including Game Plan Financial Advisors LLC and Renaissance Technologies LLC. Company insiders that have bought Cellectar Biosciences stock in the last two years include James V Caruso and Jarrod Longcor. View Insider Buying and Selling for Cellectar Biosciences.

Shares of CLRB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CLRB stock can currently be purchased for approximately $2.58.

Cellectar Biosciences has a market capitalization of $24.25 million. The biopharmaceutical company earns $-13,240,000.00 in net income (profit) each year or ($4.66) on an earnings per share basis. Cellectar Biosciences employs 7 workers across the globe.View Additional Information About Cellectar Biosciences.

The official website for Cellectar Biosciences is http://www.cellectar.com/.

Cellectar Biosciences' mailing address is 100 CAMPUS DRIVE, FLORHAM PARK NJ, 07932. The biopharmaceutical company can be reached via phone at 608-441-8120 or via email at [email protected]